Literature DB >> 1449524

Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP(dAMP) kinase from L1210 cells.

A Merta1, I Votruba, J Jindrich, A Holý, T Cihlár, I Rosenberg, M Otmar, T Y Herve.   

Abstract

Acyclic nucleotide analogues 9-(2-phosphonomethoxyethyl)adenine (PMEA) and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine ((S)-HPMPA) which display potent antiviral activity are transformed in the cells to their mono- and disphosphoryl derivatives. We purified from mouse L1210 cells the enzyme that in two steps phosphorylates PMEA and (S)-HPMPA to their diphosphoryl derivatives and found that it co-purifies with AMP(dAMP) kinase activity; the best substrates of this enzyme were AMP, ADP and dAMP. Other nucleoside 5'-triphosphates or creatine phosphate could not be substituted for ATP as a phosphate donor. Our results also indicated that at least one other enzyme (creatine kinase) is capable of transforming the monophosphoryl derivatives of the studied compounds to their respective diphosphates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1449524     DOI: 10.1016/0006-2952(92)90110-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

Review 1.  Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Authors:  K C Cundy
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

2.  Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.

Authors:  L Naesens; J Balzarini; N Bischofberger; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice.

Authors:  J Balzarini; T Vahlenkamp; H Egberink; K Hartmann; M Witvrouw; C Pannecouque; P Casara; J F Navé; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 4.  Alpha-carboxynucleoside phosphonates: direct-acting inhibitors of viral DNA polymerases.

Authors:  Jan Balzarini; Alan Ford; Nuala M Maguire; Jubi John; Kalyan Das; Eddy Arnold; Wim Dehaen; Anita Maguire
Journal:  Future Med Chem       Date:  2019-01-16       Impact factor: 3.808

Review 5.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

Review 6.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

7.  Transport of 9-(2-phosphonomethoxyethyl)adenine across plasma membrane of HeLa S3 cells is protein mediated.

Authors:  T Cihlár; I Rosenberg; I Votruba; A Holý
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.

Authors:  J Balzarini; A Holy; J Jindrich; L Naesens; R Snoeck; D Schols; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice.

Authors:  Sanaa Botros; Samia William; Olfat Hammam; Zdenĕk Zídek; Antonín Holý
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 10.  Acyclic nucleosides as antiviral compounds.

Authors:  S Freeman; J M Gardiner
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.